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Abstract: Hypertension is an atherosclerosis factor and is associated with cardiovascular risk. We in-
vestigated the relationship between hypertension and the presence, extent, and severity of coronary
atherosclerosis in coronary computed tomographic angiography and cardiac events risk. Of 17 181 pa-
tients enrolled in the CONFIRM registry (Coronary CT Angiography Evaluation for Clinical Outcomes:
An International Multicenter Registry) who underwent ￿64-detector row coronary computed tomographic
angiography, we identified 14 803 patients without known coronary artery disease. Of these, 1434 hyper-
tensive patients were matched to 1434 patients without hypertension. Major adverse cardiac events risk of
hypertension and non-hypertensive patients was evaluated with Cox proportional hazards models. The
prognostic associations between hypertension and no-hypertension with increasing degree of coronary
stenosis severity (nonobstructive or obstructive ￿50%) and extent of coronary artery disease (segment
involvement score of 1-5, >5) was also assessed. Hypertension patients less commonly had no coronary
atherosclerosis and more commonly had nonobstructive and 1-, 2-, and 3-vessel disease than the no-
hypertension group. During a mean follow-up of 5.2±1.2 years, 180 patients experienced cardiac events,
with 104 (2.0%) occurring in the hypertension group and 76 (1.5%) occurring in the no-hypertension
group (hazard ratios, 1.4; 95% confidence intervals, 1.0-1.9). Compared with no-hypertension patients
without coronary atherosclerosis, hypertension patients with no coronary atherosclerosis and obstructive
coronary disease tended to have higher risk of cardiac events. Similar trends were observed with respect
to extent of coronary artery disease. Compared with no-hypertension patients, hypertensive patients
have increased presence, extent, and severity of coronary atherosclerosis and tend to have an increase in
major adverse cardiac events.
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1Abstract—Hypertension is an atherosclerosis factor and is associated with cardiovascular risk. We investigated the 
relationship between hypertension and the presence, extent, and severity of coronary atherosclerosis in coronary 
computed tomographic angiography and cardiac events risk. Of 17 181 patients enrolled in the CONFIRM registry 
(Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry) who underwent 
≥64-detector row coronary computed tomographic angiography, we identified 14 803 patients without known coronary 
artery disease. Of these, 1434 hypertensive patients were matched to 1434 patients without hypertension. Major adverse 
cardiac events risk of hypertension and non-hypertensive patients was evaluated with Cox proportional hazards models. 
The prognostic associations between hypertension and no-hypertension with increasing degree of coronary stenosis 
severity (nonobstructive or obstructive ≥50%) and extent of coronary artery disease (segment involvement score of 1–5, 
>5) was also assessed. Hypertension patients less commonly had no coronary atherosclerosis and more commonly had 
nonobstructive and 1-, 2-, and 3-vessel disease than the no-hypertension group. During a mean follow-up of 5.2±1.2 years, 
180 patients experienced cardiac events, with 104 (2.0%) occurring in the hypertension group and 76 (1.5%) occurring 
in the no-hypertension group (hazard ratios, 1.4; 95% confidence intervals, 1.0–1.9). Compared with no-hypertension 
patients without coronary atherosclerosis, hypertension patients with no coronary atherosclerosis and obstructive coronary 
disease tended to have higher risk of cardiac events. Similar trends were observed with respect to extent of coronary artery 
disease. Compared with no-hypertension patients, hypertensive patients have increased presence, extent, and severity of 
coronary atherosclerosis and tend to have an increase in major adverse cardiac events.  (Hypertension. 2017;70:00-00. 
DOI: 10.1161/HYPERTENSIONAHA.117.09402.)
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Hypertension affects almost one third of adults, including >7 million patients in the United States1–3 and is strongly 
associated with cardiovascular morbidity and mortality.4–9 
Although hypertension is a well-established risk factor for cor-
onary artery disease (CAD),10 the relationships between hyper-
tension and coronary atherosclerotic plaque stenosis, extent, 
characteristics, and major adverse cardiac events (MACE) risk 
have not been examined. Coronary computed tomographic 
angiography (CTA) has emerged as an accurate noninvasive 
modality to evaluate coronary atherosclerotic plaque and 
assess the risk of patients with suspected CAD.11–14 In this 
study, we used coronary CTA to investigate the relationship 
between hypertension and the presence, extent, and severity of 
CAD and to explore whether hypertension adds to the assess-
ment of atherosclerosis in prediction of MACE.
Methods
Study Population
From 17 181 patients enrolled in the CONFIRM (Coronary CT 
Angiography Evaluation for Clinical Outcomes: An International 
Multicenter Registry) registry between 2002 and 2011 who under-
went ≥64-detector row coronary CTA at 17 centers, we identified 
14 803 patients without known CAD who underwent coronary CTA. 
Of those, we sequentially excluded patients without information on 
MACE (n=6889), early revascularization <3 months after coronary 
CTA (n=1212), and any risk factors used for matching (n=2272), 
resulting in a population of 4430 patients. Hypertensive and nonhy-
pertensive subjects were matched for age, sex, all other CAD risk 
factors, including diabetes mellitus, dyslipidemia, current smoking, 
family history, chest pain symptoms (asymptomatic, atypical, noncar-
diac, and typical chest pain), and dyspnea using propensity scores.15 
The resulting propensity score was then applied 1:1 to match every 
hypertensive subject (n=2791) to a corresponding nonhypertensive 
subject (n=1639) using a Mahalanobis nearest-neighbor matching 
algorithm with caliper <0.01.15 After matching, 2868 patients (age 
56.4±11.1 years, male 60.8%) comprised the final study popula-
tion, with 1434 patients with hypertension and 1434 patients with-
out hypertension. The study was followed by Declaration of Helsinki 
Guidelines, and each institution obtained Institutional Review Board 
approval. All patients had signed informed consent.
Prescan Risk Factor Assessment
All CAD risk factors were prospectively ascertained before the 
coronary CTA examination by direct patient interview by a physi-
cian or nurse research coordinator and by standardized site sur-
veys. Hypertension was defined as a history of physician-diagnosed 
high blood pressure or treatment with blood pressure medications. 
Dyslipidemia was defined as physician-diagnosed dyslipidemia or 
current treatment with lipid-lowering medications. Diabetes mellitus 
was defined by physician-diagnosed diabetes mellitus or use of insu-
lin or oral hypoglycemic agents. A smoking history was defined as 
current smoking or cessation of smoking within 3 months of testing. 
Family history of CAD was determined by self-report. Chest symp-
tom characteristics (asymptomatic, atypical, noncardiac, and typical 
chest pain and dyspnea) were recorded.16
Imaging Analysis
Coronary CTA was performed using multidetector CT scanners with 
≥64 slices detector rows as previously described.14,17 CT data sets 
were evaluated for the presence of any plaque and plaque composition 
(stenosis and extent) on coronary CTA, using a modified 16-segment 
American Heart Association coronary tree model in accordance with 
the Society of Cardiovascular Computed Tomographic guidelines.18 
Coronary plaque was identified as hyperdense structure adjacent to 
lumen of any size or hypodense structure distinct from lumen and 
per-arterial tissue >1 mm2 in largest area. Severity of luminal steno-
sis was classified into 3 groups: none (0% luminal stenosis), nonob-
structive (1%–49% luminal stenosis), and obstructive stenosis (≥50% 
luminal stenosis). For per-vessel analysis, we used a 5-group catego-
rization: no plaque, nonobstructive CAD, and presence of obstructive 
CAD in 1, 2, or 3 vessels. Left main disease was categorized as a 3-ves-
sel CAD equivalent. For measures of CAD extent and distribution, the 
segment involvement score (SIS) was defined as the total number of 
coronary artery segments involved with any plaque.13 For per-location 
analysis, we used a 5-group categorization: left main, proximal, mid 
and distal coronary segments, and side branches, including diagonal 
branches, obtuse marginal branches, posterior descending artery, and 
posterior lateral branch. Detected plaques were visually classified as 
noncalcified plaque (containing no calcification), partially calcified 
plaque (containing calcification and noncalcified plaque), or calcified 
plaque (containing only calcification).
Statistical Analysis
Continuous variables were expressed as the mean±SD. The Wilcoxon 
rank-sum test (for nonparametrically distributed variables) was used 
to conduct intergroup comparisons between no-hypertension and 
hypertension groups. Categorical variables were compared using 
Pearson χ2 tests.
MACE was defined as all-cause death or nonfatal myocardial 
infarction. Myocardial infarction was defined by site physicians in 
accordance with American College of Cardiology/American Heart 
Association guidelines and the World Health Organization Universal 
Definition of Myocardial Infarction.19,20 The log-rank test was used 
for comparing MACE event rates between the hypertension and no-
hypertension groups, and MACE-free survival was further assessed 
using Cox proportional hazards models and Kaplan–Meier survival 
curves. We also assessed MACE risk by Cox proportional hazards 
models in men and women.
In addition, degrees of stenosis severity (normal, nonobstructive, 
and obstructive CAD ≥50%) and extent of CAD (SIS of 0, 1–5, and 
>5) were assessed among no-hypertension and hypertension groups in 
relation to time to MACE by Cox proportional hazards models. Scaled 
Schoenfeld residuals were used to verify the assumption of propor-
tional hazards of the Cox models.21 Hazard ratios (HRs) and 95% 
confidence intervals (CIs) were calculated from the Cox models. Area 
under the curves (AUC) by receiver operator characteristics for predic-
tion of MACE were used to evaluate the added value of hypertension 
over assessment of coronary atherosclerosis alone (≥50% stenosis or 
SIS) or the combination of coronary atherosclerosis and clinical fac-
tors other than hypertension (other clinical factors [age, sex, diabetes 
mellitus, dyslipidemia, current smoking, family history, and all chest 
symptoms]). We also calculated continuous net reclassification index 
(cNRI)22 between the models to investigate whether hypertension re-
classified patients with respect to MACE risk over the combination of 
other clinical risk factors and atherosclerosis variables.
All statistical calculations were performed using STATA (Version 
11.2; StataCorp LP, College Station, TX) for Windows.
Results
Patient Characteristics
Table 1 demonstrates the baseline characteristics among 
patients with and without hypertension. Propensity matching 
resulted in no differences between the groups in age, male 
sex, other CAD risk factors, and all chest symptoms (P>0.05 
for all).
CAD Characteristics on Coronary CTA
Extent and severity of CAD as observed on coronary CTA 
in patients with and without hypertension are shown in 
Table 2. About plaque extent and severity stenosis, compared 
with the no-hypertension patients, hypertension patients 
manifested a greater SIS and a lower prevalence of absent 
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plaque. Hypertension patients possessed greater preva-
lence of obstructive lesions in 1, 2, or 3 vessels (P<0.001). 
Hypertension patients had more ≥50% stenosis in the proxi-
mal and mid coronary arteries and side branches. On plaque 
characteristics, any noncalcified plaque or calcified plaque 
was more observed in hypertension patients compared with 
no-hypertension patients (Table 2).
MACE Risk
One-hundred eighty patients (6.3% of study population) 
experienced MACE at a mean follow-up of 5.2±1.2 years, 
occurring in 104 patients of the hypertension group and 76 
patients of the no-hypertension group (42 deaths, 34 nonfatal 
myocardial infarction; 7.3% versus 5.3%, P=0.03; Tables 3 
and 4). Kaplan–Meier curve demonstrated that MACE were 
more common in the hypertension versus the no-hypertension 
subjects (P<0.01; Figure 1). By Cox proportional analysis, 
hypertension subjects experienced higher MACE risk than 
no-hypertension subjects (HR, 1.4; 95% CI, 1.0–1.9; P=0.03). 
On a subanalysis by sex, in both of men and women, MACE 
tended to be more common in the hypertension versus the no-
hypertension subjects (HR, 1.4; 95% CI, 0.9–2.0; P=0.12 for 
men, and HR, 1.4; 95% CI, 0.9–2.3; P=0.14 for women).
Considering the CTA findings, the risk of MACE was pro-
gressively higher in the subjects with nonobstructive CAD and 
those with obstructive CAD when compared with those with 
no-CAD (Figure 2A). A trend toward a higher odds ratio was 
observed among hypertension patients with normal coronary 
arteries; however, it did not reach statistical significance (HR, 
1.9; 95% CI, 1.0–3.6; P=0.06). In patients with nonobstruc-
tive CAD, the HRs of the hypertension and no-hypertension 
groups were similar. In the obstructive CAD group, the HR in 
the hypertension group was only slightly higher than that in 
the no-hypertension group (Figure 2A).
On the extent of CAD, similar findings were observed. 
The risk of MACE was also progressively higher in the sub-
jects with SIS of 1 to 5 and those with SIS of >5 when com-
pared with those with no-CAD. The HRs of the hypertension 
group in the SIS of 1 to 5 and SIS of >5 groups were only 
slightly higher than the no-hypertension group (Figure 2B).
The incremental added value of hypertension in prediction 
of MACE over clinical and CTA variables is shown in Table 
4. The presence of obstructive CAD was predictive of MACE 
(model 1; AUC, 0.648). The combination of other clinical fac-
tors increased this prediction (model 2; P<0.0001 for cNRI 
and P<0.0001 for AUC). When hypertension was then added 
(model 3), there was a significant increase in cNRI (P=0.03), 
and a trend toward increase in the AUC (P=0.055). Similar 
Table 1. Clinical Characteristics (n=2868)
Clinical Characteristics
No Hypertension 
(n=1434)
Hypertension 
(n=1434) P Value
Age 56.3±11.0 56.6±11.1 0.47
Male sex (%) 60.8 60.8 1.00
Diabetes mellitus (%) 7.5 8.5 0.30
Dyslipidemia (%) 48.0 49.0 0.60
Smoking (%) 16.5 18.3 0.20
Family history (%) 33.3 34.8 0.41
Chest pain status (%)
  Asymptomatic 39.8 37.7
0.17
  Noncardiac 14.2 15.8
  Atypical 37.3 35.9
  Typical 8.8 10.7
Dyspnea 12.8 14.6 0.44
Table 2. CAD Characteristics on Coronary CTA (n=2868)
CAD Characteristics on 
Coronary CTA
No Hypertension 
(n=1434)
Hypertension 
(n=1434) P Value
SIS (median; IQR) 0 (0–2) 1 (0–3) <0.0001
No. of vessels with plaque and ≥50% stenosis (%)
  No plaque 53.0 43.7
<0.001
  Nonobstructive plaque 
(1%–49%)
33.3 37.7
  1-vessel disease (≥50%) 9.5 12.1
  2-vessel disease (≥50%) 2.6 4.4
  3-vessel disease (≥50%)/
Left main
1.6 2.2
Distribution for any coronary artery disease (%)
  Left main 12.6 14.1 0.24
  Proximal 38.2 46.6 <0.001
  Mid 29.3 36.0 <0.001
  Distal 14.1 18.6 0.002
  Side branches 14.7 18.4 0.01
Distribution for coronary artery disease with ≥50% stenosis (%)
  Left main 0.3 0.6 0.18
  Proximal 7.5 10.0 0.02
  Mid 8.2 10.3 0.06
  Distal 3.4 4.6 0.12
  Side branches 4.7 7.0 0.01
Plaque characteristics (%)
  Noncalcified plaque 13.2 17.8 0.001
  Partially calcified plaque 19.5 22.2 0.08
  Calcified plaque 24.3 28.2 0.02
CAD indicates coronary artery disease; CTA, computed tomographic 
angiography; IQR, interquartile range; and SIS, segment involvement score.
Table 3. MACE Risk
MACE Risk
MACE
No Hypertension 
(n=1434)
Hypertension 
(n=1434) P Value
MACE (%, n) 5.3 (76) 7.3 (104) 0.03
Deaths (%, n) 2.9 (42) 3.9 (56)  
Nonfatal MI (%, n) 2.4 (34) 3.4 (48)  
MACE indicates major adverse cardiac events; and MI, myocardial infarction.
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results were observed with respect to the extent of CAD. The 
SIS alone was predictive MACE (model 4; AUC, 0.678). The 
combination of other clinical factors increased this prediction 
(model 5; P<0.0001 for cNRI and P=0.0001 for AUC). When 
hypertension was added (model 6), a significant increase in 
cNRI (P=0.03) and an increase in the AUC were observed 
(P=0.052).
Discussion
This study demonstrated that patients with hypertension had 
more advanced coronary atherosclerosis by coronary CTA and 
future MACE risk compared with those without hypertension. 
When stratifying by sex, there was a trend toward increased 
MACE risk in hypertension in both men and women. Patients 
with hypertension more frequently had any CAD, with higher 
prevalence of any CAD and of 1-, 2-, and 3-vessel obstruc-
tive CAD in each category, as well as CAD ≥50% stenosis in 
the proximal, mid, and side branches. Hypertension patients 
also had greater prevalence of any noncalcified plaque and 
calcified plaque. When stratifying by the extent and severity 
of CAD, MACE risk in the hypertension group was slightly 
higher than that in the non-hypertension group across the 
CAD categories. There was a trend toward incremental pre-
dictive value of hypertension over other risk factors and the 
extent or severity of CAD.
It is well known that hypertension is a main cardiovas-
cular risk factor and related to worsening prognosis.4,5,7–9 To 
our knowledge, however, no previous studies have shown the 
direct relation of hypertension to CAD characteristics, includ-
ing the presence, extent, and severity of CAD on coronary 
CTA and MACE risk that is described in this article.
Using the current registry, our group previously reported 
the relationship between diabetes mellitus and current smok-
ing and the presence, extent, and severity of coronary athero-
sclerosis on coronary CTA, as well as the relationship of the 
coronary CTA findings to future adverse outcomes.23,24 The 
findings of this study suggest that the presence of hyperten-
sion per se may not add as much incremental prognostic value 
as these other risk factors after taking into account the pres-
ence, extent, and severity of coronary CTA.
Hypertension has been previously shown to be a predictor 
of the extent of coronary atherosclerosis as assessed by coro-
nary artery calcium.25 Both diabetes mellitus and smoking were 
found to be stronger predictors of coronary atherosclerosis 
than hypertension. Extensive epidemiological data have also 
demonstrated that hypertension is an independent risk factor 
for coronary atherosclerosis and for future cardiac events,26,27 
but that it is less strong a predictor than diabetes mellitus and 
smoking.25 Our findings are concordant with the previous data 
with respect to coronary atherosclerosis, including a relation-
ship to increasing amounts of obstructive CAD and with show-
ing a trend toward association with MACE events.
How hypertension results in increase in coronary athero-
sclerosis has been extensively studied. The principal under-
lying pathophysiologic mechanism is considered to be a 
mechanical one related to pulse pressure.28 Wide pulse pres-
sure has been reported to be associated with increased cardiac 
events.29–33 Both increased pulse pressure and systolic pres-
sure contribute to endothelial dysfunction, which facilitates 
the entry of low-density lipid cholesterol into the blood vessel 
Figure 1. Kaplan–Meier curve for major adverse cardiac events 
(MACE) in patients with no known coronary artery disease (CAD) 
among the absence and presence of hypertension (HT).
Table 4. Predictors of MACE
Predictors of MACE
Models cNRI (95% CI) P Value
% Events 
Reclassified
% Nonevents 
Reclassified AUC
AUC P 
Value
Stenosis severity of CAD
  Model 1 … … … … 0.648  
  Model 2 (vs model 1) 0.39 (0.24–0.54) <0.0001 14%, P=0.053 24%, P<0.0001 0.729 <0.0001
  Model 3 (vs model 2) 0.17 (0.02–0.32) 0.03 16%, P=0.04 1%, P=0.59 0.734 0.055
Extent of CAD
  Model 4 … … … … 0.678  
  Model 5 (vs model 4) 0.41 (0.26–0.56) <0.0001 17%, P=0.03 24%, P<0.0001 0.721 0.001
  Model 6 (vs model 5) 0.17 (0.02–0.32) 0.03 16%, P=0.04 1%, P=0.59 0.726 0.052
Model 1: Stenosis severity ≥50%. Model 2: Age, sex, and other risk factors+stenosis severity ≥50%. Model 3: Age, sex, and 
other risk factors+stenosis severity ≥50%+HT. Model 4: SIS. Model 5: Age, sex, and other risk factors+SIS. Model 6: Age, sex, and 
other risk factors+SIS+HT. Other risk factors are diabetes mellitus, dyslipidemia, smoking, family history, and chest symptoms. AUC 
indicates area under the curve; CAD, coronary artery disease; CI, confidence interval; cNRI, continuous net reclassification index; HT, 
hypertension; MACE, major adverse cardiac events; MI, myocardial infarction; and SIS, segment involvement score.
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wall, initiating the atherosclerotic process.34 Hypertension also 
is a cause of left ventricular hypertrophy (LVH),35,36 which 
has been implicated as a cause of coronary atherosclerosis, 
myocardial infarction, arrhythmia, cardiac failure, or cardiac 
death.34,37–39 LVH is associated with collagen deposition within 
the left ventricle.34 This process is considered to explain the 
frequent association of LVH with midmyocardial scarring on 
cardiovascular magnetic resonance, which is associated with 
increase in cardiac events.40
Of interest, in this study, in patients with no evidence of 
CAD on coronary CTA, those with hypertension had a >2-
fold MACE risk compared to those with no-hypertension. 
An increased risk of events in these patients could have been 
related to LVH; however, information on LVH was not present 
in the CONFIRM database.
Limitations
There are several limitations in this study. Data on duration 
and severity of hypertension, as well as information on LVH, 
did not exist in the current registry. Information was not uni-
formly available on specific antihypertensive medications at 
the time of testing. Further, no information was available on 
the effectiveness of blood pressure control after testing which 
may have affected MACE risk.41 We have included vari-
ous CAD descriptors, including the extent, stenosis severity, 
basic characteristics, and location of CAD. However, other 
variables, such as vulnerable plaque features or bifurcation 
lesions, that might be associated with MACE risk were not 
available in this study. The number of events by sex was small 
and may have led to the finding that a trend toward increased 
MACE divided by sex was not statistically significant.
Perspectives
Compared with patients without hypertension, hypertensive 
patients have increased presence, extent, and severity of coro-
nary atherosclerosis and tend to have an increase in MACE 
events. The findings support the concept of lifestyle modifica-
tion regardless of sex to optimize CAD risk factors, including 
hypertension, to reduce future cardiovascular events as sug-
gested by current guidelines.42
Conclusions
Hypertensive patients had greater amount of coronary athero-
sclerosis and greater risk of MACE compared with nonhy-
pertensive patients, independent of other clinical risk factors 
and of the presence of obstructive CAD or extent of CAD. 
Further, hypertensive individuals with an increasing degree of 
CAD stenosis severity and extent of CAD experienced mod-
estly increase rates of MACE compared with nonhypertensive 
patients.
Disclosures
J.K. Min received modest speakers’ bureau medical advisory 
board compensation and significant research support from GE 
Healthcare. D.S. Berman received grant funding from Siemens 
and GE Healthcare. S. Achenbach received grant support from 
Siemens and Bayer Schering Pharma and has served as a consul-
tant for Servier. M. Al-Mallah received support from the American 
Heart Association, BCBS Foundation of Michigan, and Astellas. F. 
Cademartiri has served on the Speakers’ Bureau of Guerbet and is 
a consultant for Guerbet, Servier, and Somahlution. K. Chinnaiyan 
received grant support from Bayer Pharma and Blue Cross Blue 
Shield Blue Care MI. B.J.W. Chow received research and fellow-
ship support from GE Healthcare, research support from Pfizer and 
AstraZeneca, and educational support from TeraRecon. G. Pontone 
received grant support from GE Healthcare and Heartflow, and has 
served on the Speakers’ Bureau of GE Healthcare, Bracco, and 
Medtronic. J. Hausleiter received a research grant from Siemens 
Medical Systems. P.A. Kaufmann received institutional research 
support from GE Healthcare and grant support from Swiss National 
Science Foundation. G. Raff received grant support from Siemens, 
Blue Cross Blue Shield Blue Care MI, and Bayer Pharma. All other 
authors report no conflicts.
References
 1. Ostchega Y, Yoon SS, Hughes J, Louis T. Hypertension awareness, treat-
ment, and control–continued disparities in adults: United States, 2005–
2006. NCHS Data Brief. 2008;3:1–8.
 2. Centers for Disease Control and Prevention (CDC). Vital signs: preva-
lence, treatment, and control of hypertension–United States, 1999–2002 
and 2005–2008. MMWR Morb Mortal Wkly Rep. 2011;60:103–108.
 3. Roger VL, Go AS, Lloyd-Jones DM, et al; American Heart Association 
Statistics Committee and Stroke Statistics Subcommittee. Heart dis-
ease and stroke statistics–2012 update: a report from the American 
Heart Association. Circulation. 2012;125:e2–e220. doi: 10.1161/
CIR.0b013e31823ac046.
Figure 2. A, Left, Cox proportional hazard models by normal, nonobstructive, and obstructive coronary artery disease (CAD) among no-
hypertension (no-HT) and hypertension (HT) groups. B, Right, Cox proportional hazard models by segment involvement score (SIS) 0, 1 
to 5, and >5 among no-HT and HT groups.
 by guest on June 21, 2017
http://hyper.ahajournals.org/
D
ow
nloaded from
 
6  Hypertension  August 2017
 4. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ; Comparative 
Risk Assessment Collaborating Group. Selected major risk factors and 
global and regional burden of disease. Lancet. 2002;360:1347–1360. doi: 
10.1016/S0140-6736(02)11403-6.
 5. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, 
Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard 
RH. Risks of untreated and treated isolated systolic hypertension in the 
elderly: meta-analysis of outcome trials. Lancet. 2000;355:865–872.
 6. Ezzati M, Vander Hoorn S, Lawes CM, Leach R, James WP, Lopez AD, 
Rodgers A, Murray CJ. Rethinking the “diseases of affluence” paradigm: 
global patterns of nutritional risks in relation to economic development. 
PLoS Med. 2005;2:e133. doi: 10.1371/journal.pmed.0020133.
 7. Messerli FH. Hypertension and sudden cardiac death. Am J Hypertens. 
1999;12:181S–188S.
 8. Koyanagi S, Eastham C, Marcus ML. Effects of chronic hypertension 
and left ventricular hypertrophy on the incidence of sudden cardiac 
death after coronary artery occlusion in conscious dogs. Circulation. 
1982;65:1192–1197.
 9. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 
1998;98:2334–2351.
 10. Kaplan NM, Opie LH. Controversies in hypertension. Lancet. 
2006;367:168–176. doi: 10.1016/S0140-6736(06)67965-8.
 11. Budoff MJ, Dowe D, Jollis JG, Gitter M, Sutherland J, Halamert E, 
Scherer M, Bellinger R, Martin A, Benton R, Delago A, Min JK. 
Diagnostic performance of 64-multidetector row coronary computed 
tomographic angiography for evaluation of coronary artery stenosis in 
individuals without known coronary artery disease: results from the pro-
spective multicenter ACCURACY (Assessment by Coronary Computed 
Tomographic Angiography of Individuals Undergoing Invasive Coronary 
Angiography) trial. J Am Coll Cardiol. 2008;52:1724–1732. doi: 
10.1016/j.jacc.2008.07.031.
 12. Meijboom WB, Meijs MF, Schuijf JD, et al. Diagnostic accuracy of 
64-slice computed tomography coronary angiography: a prospective, mul-
ticenter, multivendor study. J Am Coll Cardiol. 2008;52:2135–2144. doi: 
10.1016/j.jacc.2008.08.058.
 13. Min JK, Shaw LJ, Devereux RB, Okin PM, Weinsaft JW, Russo DJ, 
Lippolis NJ, Berman DS, Callister TQ. Prognostic value of multidetec-
tor coronary computed tomographic angiography for prediction of all-
cause mortality. J Am Coll Cardiol. 2007;50:1161–1170. doi: 10.1016/j.
jacc.2007.03.067.
 14. Min JK, Dunning A, Lin FY, et al; CONFIRM Investigators. Age- and 
sex-related differences in all-cause mortality risk based on coronary com-
puted tomography angiography findings results from the International 
Multicenter CONFIRM (Coronary CT Angiography Evaluation for 
Clinical Outcomes: An International Multicenter Registry) of 23,854 
patients without known coronary artery disease. J Am Coll Cardiol. 
2011;58:849–860. doi: 10.1016/j.jacc.2011.02.074.
 15. Imbens G. The role of propensity score in estimating dose-response func-
tions. 2000;87:706–710.
 16. Abidov A, Rozanski A, Hachamovitch R, Hayes SW, Aboul-Enein F, 
Cohen I, Friedman JD, Germano G, Berman DS. Prognostic significance 
of dyspnea in patients referred for cardiac stress testing. N Engl J Med. 
2005;353:1889–1898. doi: 10.1056/NEJMoa042741.
 17. Min JK, Dunning A, Lin FY, et al. Rationale and design of the CONFIRM 
(COronary CT Angiography EvaluatioN For Clinical Outcomes: An 
InteRnational Multicenter) Registry. J Cardiovasc Comput Tomogr. 
2011;5:84–92. doi: 10.1016/j.jcct.2011.01.007.
 18. Abbara S, Arbab-Zadeh A, Callister TQ, Desai MY, Mamuya W, Thomson 
L, Weigold WG. SCCT guidelines for performance of coronary computed 
tomographic angiography: a report of the Society of Cardiovascular 
Computed Tomography Guidelines Committee. J Cardiovasc Comput 
Tomogr. 2009;3:190–204. doi: 10.1016/j.jcct.2009.03.004.
 19. Anderson JL, Adams CD, Antman EM, et al; American College of 
Cardiology; American Heart Association Task Force on Practice Guidelines 
(Writing Committee to Revise the 2002 Guidelines for the Management of 
Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction); 
American College of Emergency Physicians; Society for Cardiovascular 
Angiography and Interventions; Society of Thoracic Surgeons; American 
Association of Cardiovascular and Pulmonary Rehabilitation; Society 
for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the 
management of patients with unstable angina/non-ST-Elevation myocar-
dial infarction: a report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines (Writing Committee 
to Revise the 2002 Guidelines for the Management of Patients With 
Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed 
in collaboration with the American College of Emergency Physicians, 
the Society for Cardiovascular Angiography and Interventions, and the 
Society of Thoracic Surgeons endorsed by the American Association 
of Cardiovascular and Pulmonary Rehabilitation and the Society for 
Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1–e157. 
doi: 10.1016/j.jacc.2007.02.013.
 20. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task 
Force for the Redefinition of Myocardial Infarction. Universal definition 
of myocardial infarction. J Am Coll Cardiol. 2007;50:2173–2195. doi: 
10.1016/j.jacc.2007.09.011.
 21. Grambsch P. Proportional hazards tests and diagnostics based on weighted 
residuals. 1994;81:515–526.
 22. Pencina MJ, D’Agostino RB Sr, Steyerberg EW. Extensions of net reclas-
sification improvement calculations to measure usefulness of new bio-
markers. Stat Med. 2011;30:11–21. doi: 10.1002/sim.4085.
 23. Rana JS, Dunning A, Achenbach S, et al. Differences in prevalence, extent, 
severity, and prognosis of coronary artery disease among patients with 
and without diabetes undergoing coronary computed tomography angi-
ography: results from 10,110 individuals from the CONFIRM (COronary 
CT Angiography EvaluatioN For Clinical Outcomes): an InteRnational 
Multicenter Registry. Diabetes Care. 2012;35:1787–1794. doi: 10.2337/
dc11-2403.
 24. Nakanishi R, Berman DS, Budoff MJ, et al. Current but not past smok-
ing increases the risk of cardiac events: insights from coronary com-
puted tomographic angiography. Eur Heart J. 2015;36:1031–1040. doi: 
10.1093/eurheartj/ehv013.
 25. Kronmal RA, McClelland RL, Detrano R, Shea S, Lima JA, Cushman M, 
Bild DE, Burke GL. Risk factors for the progression of coronary artery 
calcification in asymptomatic subjects: results from the Multi-Ethnic 
Study of Atherosclerosis (MESA). Circulation. 2007;115:2722–2730. 
doi: 10.1161/CIRCULATIONAHA.106.674143.
 26. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al; American College 
of Cardiology/American Heart Association Task Force on Practice 
Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovas-
cular risk: a report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 
2014;63(25 pt B):2935–2959. doi: 10.1016/j.jacc.2013.11.005.
 27. Conroy RM, Pyörälä K, Fitzgerald AP, et al; SCORE project group. 
Estimation of ten-year risk of fatal cardiovascular disease in Europe: 
the SCORE project. Eur Heart J. 2003;24:987–1003. doi: 10.1016/
S0195-668X(03)00114-3.
 28. Lee TM, Lin YJ, Su SF, Chien KL, Chen MF, Liau CS, Lee YT. Relation 
of systemic arterial pulse pressure to coronary atherosclerosis in patients 
with mitral stenosis. Am J Cardiol. 1997;80:1035–1039.
 29. Verdecchia P, Schillaci G, Reboldi G, Franklin SS, Porcellati C. Different 
prognostic impact of 24-hour mean blood pressure and pulse pressure on 
stroke and coronary artery disease in essential hypertension. Circulation. 
2001;103:2579–2584.
 30. Benetos A, Safar M, Rudnichi A, Smulyan H, Richard JL, Ducimetieère P, 
Guize L. Pulse pressure: a predictor of long-term cardiovascular mortality 
in a French male population. Hypertension. 1997;30:1410–1415.
 31. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pres-
sure and blood pressure reduction to the incidence of myocardial infarc-
tion. Hypertension. 1994;23:395–401.
 32. Mitchell GF, Moyé LA, Braunwald E, Rouleau JL, Bernstein V, Geltman 
EM, Flaker GC, Pfeffer MA. Sphygmomanometrically determined pulse 
pressure is a powerful independent predictor of recurrent events after 
myocardial infarction in patients with impaired left ventricular function. 
SAVE investigators. Survival and Ventricular Enlargement. Circulation. 
1997;96:4254–4260.
 33. Blacher J, Staessen JA, Girerd X, Gasowski J, Thijs L, Liu L, Wang JG, 
Fagard RH, Safar ME. Pulse pressure not mean pressure determines 
cardiovascular risk in older hypertensive patients. Arch Intern Med. 
2000;160:1085–1089.
 34. Frohlich ED. State of the Art lecture. Risk mechanisms in hypertensive 
heart disease. Hypertension. 1999;34:782–789.
 35. Khattar RS, Acharya DU, Kinsey C, Senior R, Lahiri A. Longitudinal asso-
ciation of ambulatory pulse pressure with left ventricular mass and vascu-
lar hypertrophy in essential hypertension. J Hypertens. 1997;15:737–743.
 36. Pannier B, Brunel P, el Aroussy W, Lacolley P, Safar ME. Pulse pressure 
and echocardiographic findings in essential hypertension. J Hypertens. 
1989;7:127–132.
 37. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular 
mass and hypertrophy are associated with increased risk for sudden death. 
J Am Coll Cardiol. 1998;32:1454–1459.
 by guest on June 21, 2017
http://hyper.ahajournals.org/
D
ow
nloaded from
 
Nakanishi et al  MACE in Hypertensive Patients With Coronary CT  7
 38. Vasan RS, Levy D. The role of hypertension in the pathogenesis 
of heart failure. A clinical mechanistic overview. Arch Intern Med. 
1996;156:1789–1796.
 39. Dunn FG, McLenachan J, Isles CG, Brown I, Dargie HJ, Lever AF, 
Lorimer AR, Murray GD, Pringle SD, Robertson JW. Left ventricular 
hypertrophy and mortality in hypertension: an analysis of data from the 
Glasgow Blood Pressure Clinic. J Hypertens. 1990;8:775–782.
 40. O’Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of 
myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 
2010;56:867–874. doi: 10.1016/j.jacc.2010.05.010.
 41. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial 
of intensive versus standard blood-pressure control. N Engl J Med. 
2015;373:2103–2116.
 42. Eckel RH, Jakicic JM, Ard JD, et al; American College of Cardiology/
American Heart Association Task Force on Practice Guidelines. 
2013 AHA/ACC guideline on lifestyle management to reduce car-
diovascular risk: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines. 
J Am Coll Cardiol. 2014;63(25 pt B):2960–2984. doi: 10.1016/j. 
jacc.2013.11.003.
What Is New?
•	This study is the first study showing the relation of hypertension to the 
presence, extent, and severity of coronary artery disease on coronary 
computed tomographic angiography and to risk of major adverse cardiac 
events among patients without known coronary artery disease.
What Is Relevant?
•	The presence of hypertension per se may not add as much incremental 
prognostic value as other risk factors after taking into account the pres-
ence, extent, and severity of coronary computed tomographic angiog-
raphy.
Summary
Patients with hypertension had greater prevalence of extent and 
stenosis severity of coronary artery disease and modestly in-
creased major adverse cardiac events risk compared with those 
without hypertension.
Novelty and Significance
 by guest on June 21, 2017
http://hyper.ahajournals.org/
D
ow
nloaded from
 
Hindoyan, Millie Gomez, Fay Y. Lin, James K. Min and Daniel S. Berman
Gianluca Pontone, Daniele Andreini, Ronen Rubinshtein, Jeroen Bax, Erica Jones, Niree 
Maffei, Gilbert Raff, Leslee J. Shaw, Todd C. Villines, Allison Dunning, Hugo Marques,
Ricardo Cury, Gudrun Feuchtner, Yong-Jin Kim, Jonathon Leipsic, Philipp A. Kaufmann, Erica 
Chinnaiyan, Benjamin J.W. Chow, Augustin DeLago, Martin Hadamitzky, Joerg Hausleiter,
Mouaz Al-Mallah, Filippo Cademartiri, Tracy Q. Callister, Hyuk-Jae Chang, Kavitha 
Rine Nakanishi, Lohendran Baskaran, Heidi Gransar, Matthew J. Budoff, Stephan Achenbach,
With Coronary Computed Tomographic Angiography
Relationship of Hypertension to Coronary Atherosclerosis and Cardiac Events in Patients
Print ISSN: 0194-911X. Online ISSN: 1524-4563 
Copyright © 2017 American Heart Association, Inc. All rights reserved.
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231Hypertension 
 published online June 12, 2017;Hypertension. 
 http://hyper.ahajournals.org/content/early/2017/06/12/HYPERTENSIONAHA.117.09402
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
  
 http://hyper.ahajournals.org//subscriptions/
is online at: Hypertension  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer this process is available in the
click Request Permissions in the middle column of the Web page under Services. Further information about
Office. Once the online version of the published article for which permission is being requested is located, 
 can be obtained via RightsLink, a service of the Copyright Clearance Center, not the EditorialHypertensionin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 by guest on June 21, 2017
http://hyper.ahajournals.org/
D
ow
nloaded from
 
